Quick Answer
MAXCYTE, INC. reported Total Revenue of $33.03 million for fiscal year 2025.
MAXCYTE, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $33.03M -14.5% |
$38.63M -6.4% |
$41.29M -6.7% |
$44.26M +30.6% |
$33.89M +29.5% |
$26.17M +21.0% |
| Net Income | -$44.63M -8.7% |
-$41.05M -8.3% |
-$37.92M -60.9% |
-$23.57M -23.5% |
-$19.08M -61.5% |
-$11.82M +8.4% |
| Diluted EPS | -$0.42 -7.7% |
-$0.39 -5.4% |
-$0.37 -60.9% |
-$0.23 -9.5% |
-$0.21 -23.5% |
-$0.17 +26.1% |
| Total Assets | $202.51M -15.4% |
$239.47M -10.7% |
$268.27M -6.4% |
$286.65M +0.9% |
$284.12M +448.7% |
$51.78M |
| Cash and Equivalents | $20.07M -28.0% |
$27.88M -40.0% |
$46.51M +320.3% |
$11.06M -76.8% |
$47.78M +154.8% |
$18.76M |
| Stockholders Equity | $171.49M -16.9% |
$206.25M -11.2% |
$232.17M -8.6% |
$253.97M -3.4% |
$262.90M +691.3% |
$33.23M +144.3% |
| R&D Expense | $20.82M -6.3% |
$22.23M -6.7% |
$23.82M +22.1% |
$19.51M +26.7% |
$15.41M -13.1% |
$17.73M +0.8% |
| Operating Income | -$51.90M -1.4% |
-$51.20M -6.0% |
-$48.30M -76.5% |
-$27.36M -50.4% |
-$18.19M -64.5% |
-$11.06M +11.0% |
| Gross Profit | $26.80M -15.0% |
$31.53M -13.7% |
$36.55M -6.7% |
$39.16M +29.5% |
$30.25M +29.2% |
$23.40M +22.4% |
| Shares Outstanding | 106.79M +1.0% |
105.71M +1.7% |
103.96M +1.5% |
102.40M +1.2% |
101.20M +30.8% |
77.38M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $6.83M | -16.4% | -19.7% |
| Net Income | September 30, 2025 | -$12.42M | -7.4% | -0.5% |
| Diluted EPS | September 30, 2025 | -$0.12 | -9.1% | +0.0% |
| Total Assets | September 30, 2025 | $213.48M | -14.1% | -2.9% |
| Cash and Equivalents | September 30, 2025 | $12.97M | -64.9% | -14.8% |
| Stockholders Equity | September 30, 2025 | $180.28M | -15.5% | -5.5% |
| R&D Expense | September 30, 2025 | $5.32M | +0.0% | -15.2% |
| Operating Income | September 30, 2025 | -$14.15M | -0.7% | +0.5% |
| Gross Profit | September 30, 2025 | $5.23M | -16.1% | -25.1% |
| Shares Outstanding | September 30, 2025 | 106.64M | +1.3% | +0.0% |
- MAXCYTE, INC. reported Total Revenue of $33.03 million for fiscal year 2025.
- MAXCYTE, INC. showed a decrease of -14.5% in Total Revenue compared to the prior fiscal year.
- MAXCYTE, INC. reported Net Income of -$44.63 million for fiscal year 2025.
- MAXCYTE, INC. showed a decrease of -8.7% in Net Income compared to the prior fiscal year.
- MAXCYTE, INC. reported Diluted EPS of $0.42 per share (loss) for fiscal year 2025.
- MAXCYTE, INC. showed a decrease of -7.7% in Diluted EPS compared to the prior fiscal year.
- MAXCYTE, INC. reported Total Assets of $202.51 million for fiscal year 2025.
- MAXCYTE, INC. showed a decrease of -15.4% in Total Assets compared to the prior fiscal year.
- MAXCYTE, INC. reported Cash and Equivalents of $20.07 million for fiscal year 2025.
- MAXCYTE, INC. showed a decrease of -28.0% in Cash and Equivalents compared to the prior fiscal year.
- MAXCYTE, INC. reported Stockholders Equity of $171.49 million for fiscal year 2025.
- MAXCYTE, INC. showed a decrease of -16.9% in Stockholders Equity compared to the prior fiscal year.
- MAXCYTE, INC. reported R&D Expense of $20.82 million for fiscal year 2025.
- MAXCYTE, INC. showed a decrease of -6.3% in R&D Expense compared to the prior fiscal year.
- MAXCYTE, INC. reported Operating Income of -$51.90 million for fiscal year 2025.
- MAXCYTE, INC. showed a decrease of -1.4% in Operating Income compared to the prior fiscal year.
- MAXCYTE, INC. reported Gross Profit of $26.80 million for fiscal year 2025.
- MAXCYTE, INC. showed a decrease of -15.0% in Gross Profit compared to the prior fiscal year.
- MAXCYTE, INC. reported Shares Outstanding of 106.79 million shares for fiscal year 2025.
- MAXCYTE, INC. showed an increase of +1.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: